Forbes digs into 'Pfizer's Nigerian nightmare'

As Pfizer negotiates a settlement with the Nigerian government in the long-running dispute over the Trovan drug trial there--and a U.S. federal appeals court considers whether Nigerian plaintiffs can sue the drugmaker here--Forbes delves into the background of the case, looking at documents and interviewing Pfizer officials, victims' families, and the FDA. An "unsettling look at the pitfalls of doing hurried drug trials in Third World countries," the story could be a cautionary tale for drugmakers conducting an increasing amount of research in the developing world. Report

Suggested Articles

It’s final: England won’t be covering AZ’s quick-selling Tagrisso in previously untreated non-small cell lung cancer patients with EGFR mutatations.

Top J&J meds have managed to hang onto market share in the face of new generics and biosims, but the drugmaker expects the pain to continue in 2020.

Lonza’s search for a new CEO is expected to be wrapped up this year as the CDMO homes in on a list of veterans from outside the company.